On the flip side if Morgan Stanley thought it was worthwhile buying 10% of the company at $5 per share equivalent then perhaps there's some inherent value in the shares after all.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025